About pacific biosciences of california inc. - PACB
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
PACB At a Glance
Pacific Biosciences of California, Inc.
1305 O'Brien Drive
Menlo Park, California 94025
| Phone | 1-650-521-8000 | Revenue | 160.01M | |
| Industry | Medical Specialties | Net Income | -546,376,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 3.89% | |
| Fiscal Year-end | 12 / 2026 | Employees | 485 | |
| View SEC Filings |
PACB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.506 |
| Price to Book Ratio | 105.59 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.952 |
| Enterprise Value to Sales | 6.149 |
| Total Debt to Enterprise Value | 0.714 |
PACB Efficiency
| Revenue/Employee | 329,907.216 |
| Income Per Employee | -1,126,548.454 |
| Receivables Turnover | 4.514 |
| Total Asset Turnover | 0.157 |
PACB Liquidity
| Current Ratio | 5.15 |
| Quick Ratio | 4.473 |
| Cash Ratio | 3.838 |
PACB Profitability
| Gross Margin | -199.219 |
| Operating Margin | -344.80 |
| Pretax Margin | -341.276 |
| Net Margin | -341.474 |
| Return on Assets | -53.448 |
| Return on Equity | -213.452 |
| Return on Total Capital | -77.197 |
| Return on Invested Capital | -58.239 |
PACB Capital Structure
| Total Debt to Total Equity | 13,131.838 |
| Total Debt to Total Capital | 99.244 |
| Total Debt to Total Assets | 89.585 |
| Long-Term Debt to Equity | 13,123.462 |
| Long-Term Debt to Total Capital | 99.181 |